Click HERE to view and download the 2-page CV for Dr. Ridgway.
Dr. Harry Ridgway is CSO and founder of THERAmolecular. He is Adjunct Professor (Victoria University, Institute for Sustainable Industry and Liveable Cities) and a freelance research scientist. Working at the crossroads of computational drug discovery and molecular modeling of functional nanoporous materials, Dr. Ridgway helps organizations around the globe in achieving their research visions. Since 2016, he has been engaged in computational drug design research for corporate and academic clients. He has expertise in state-of-the-art commercial and open-source chem/bioinformatics and drug-discovery platforms, including Molsoft’s internal coordinate mechanics (ICM) algorithms. Additionally, he has extensive experience in coding and application of classical mechanics and quantum-level calculations for modeling chemical reactions and for carrying out molecular dynamics (MD) simulations of polymer networks and drug-receptor complexes. Dr. Ridgway holds BSc and PhD degrees in microbiology (and a chemistry minor) from San Diego State University and UC San Diego’s Scripps Institute of Oceanography. He conducted postdoctoral studies in molecular and environmental
microbiology at the San Diego and Irvine campuses of the University of California. While at UC Irvine, and subsequently as R&D Director for Orange County Water District, he and his team pioneered studies of bacterial adhesion to synthetic polyamide membrane materials that helped guide development of next-generation biofouling resistant desalination and water reuse membranes. He was an early adopter in the late 1980s of MD simulations for investigating how microbial biopolymers interact with synthetic polymers. In 2002 he was awarded the prestigious Clarke Water Prize for contributions made in water science and technology. His current research at THERAmolecular is focused on the design of safe and effective drugs targeting hypertension, addiction, depression and related neurological disorders, such as Parkinson's Disease.